Cargando…

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy

The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography ((68)Ga-PSMA PET/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Eyben, Finn Edler, Soydal, Cigdem, von Eyben, Rie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066852/ https://www.ncbi.nlm.nih.gov/pubmed/33808350 http://dx.doi.org/10.3390/diagnostics11040622

Ejemplares similares

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer
por: von Eyben, Rie, et al.
Publicado: (2023)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis
por: von Eyben, Rie, et al.
Publicado: (2022)

Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. Cancers 2022, 14, 5461
por: von Eyben, Rie, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

(68)Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
por: Yuminaga, Yuigi, et al.
Publicado: (2021)

Changes of Radiation Treatment Concept Based on (68)Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
por: Bottke, Dirk, et al.
Publicado: (2021)

PSMA diagnostics and treatments of prostate cancer become mature
por: von Eyben, Finn Edler, et al.
Publicado: (2018)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Impact of (68)Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy
por: Bluemel, Christina, et al.
Publicado: (2016)

On the Way for Patients with Prostate Cancer to the Best Use of PSMA
por: von Eyben, Finn Edler, et al.
Publicado: (2022)

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
por: von Eyben, Finn Edler, et al.
Publicado: (2019)

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [(68)Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
por: Cegla, Paulina, et al.
Publicado: (2022)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

Separate Chinese lines for prostate cancer?
por: von Eyben, Finn Edler
Publicado: (2019)

(68)Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy
por: Haidar, Mohamad, et al.
Publicado: (2022)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer
por: Hoffmann, Manuela Andrea, et al.
Publicado: (2020)

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
por: von Eyben, Finn Edler, et al.
Publicado: (2017)

Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy
por: Bashir, Usman, et al.
Publicado: (2019)

(68)Ga-PSMA PET/CT: effect of external cooling on salivary gland uptake
por: Junqueira, Matheus Zanelatto, et al.
Publicado: (2021)

Meta-Analysis of Gene Expressions in Testicular Germ Cell Tumor Histologies
por: von Eyben, Finn Edler, et al.
Publicado: (2020)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and (68)Ga-PSMA-PET for biochemical relapse after radical prostatectomy – The PROPER 1 trial
por: Gunnlaugsson, Adalsteinn, et al.
Publicado: (2022)

Antihormone treatment differentially regulates PSA secretion, PSMA expression and (68)Ga–PSMA uptake in LNCaP cells
por: Mathy, C. S., et al.
Publicado: (2021)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

(68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making
por: Grubmüller, B., et al.
Publicado: (2017)

Improved oncological outcome after radical prostatectomy in patients staged with (68)Ga-PSMA-11 PET: a single-center retrospective cohort comparison
por: Ferraro, Daniela A., et al.
Publicado: (2020)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

(68)Ga-PSMA ligand PET/CT integrating indocyanine green-guided salvage lymph node dissection for lymph node metastasis after radical prostatectomy
por: Li, Teng-Cheng, et al.
Publicado: (2021)

Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, ((68))Ga-PSMA PET/CT, PSA, and PSA-density comparison study
por: Akkaya, Hüseyin, et al.
Publicado: (2023)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

False Positive Findings of [(18)F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels
por: Orevi, Marina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6jsm5mv0ecn8ldh4ibe5212s7o